Biogen Inc(NASDAQ:BIIB) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 21, 2016. Company reported revenue of $2.89B. Analysts estimated a revenue of $2.80B. Earnings per share were $5.21. Analysts had estimated an EPS of $4.68.
In a different note, Bernstein said it Initiates Coverage on Biogen Inc, according to a research note issued on Jun 29, 2016. The shares have been rated ‘Outperform’ by the firm. On Jun 8, 2016, Citigroup said it Maintains its rating on Biogen Inc. In the research note, the firm Lowers the price-target to $345.00 per share. The shares have been rated ‘Buy’ by the firm. On Jun 7, 2016, Citigroup said it Downgrades its rating on Biogen Inc. The shares have been rated ‘Neutral’ by the firm.
Biogen Inc (BIIB) made into the market gainers list on Wednesdays trading session with the shares advancing 1.00% or 2.59 points. Due to strong positive momentum, the stock ended at $262.41, which is also near the day’s high of $263.16. The stock began the session at $259.87 and the volume stood at 18,30,168 shares. The 52-week high of the shares is $412.24 and the 52 week low is $223.0211. The company has a current market capitalization of $57,481 M and it has 21,90,51,490 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jun 7, 2016, Adam Koppel (EVP, Strategy and Bus. Dev.) sold 555 shares at $290.00 per share price.Also, On Jun 6, 2016, George A Scangos (Chief Executive Officer) sold 842 shares at $290.00 per share price.On Feb 26, 2016, Alfred Sandrock (EVP CMO Neuro & Neurodegenerat) sold 183 shares at $261.90 per share price, according to the Form-4 filing with the securities and exchange commission.
Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.